News
Anal Cancer
Bladder Cancer
Bone Cancer
Brain Cancer
Breast Cancer
Cancer of Unknown Primary
Cervical Cancer
Colon Cancer
Esophageal Cancer
Gastric Cancer
GIST
Head & Neck Cancer
Hodgkins Lymphoma
Leukemia
Acute Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Liver Cancer
Lung Cancer
Melanoma
Mesothelioma
Multiple Myeloma
Myelodysplastic Syndrome
MPN-PV-ET-MF
Neuroblastoma
Neuroendocrine Tumors
Non Hodgkins Lymphoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Renal Cancer
Rectal Cancer
Sarcoma
Skin Care
Skin Cancer
Testicular Cancer
Thyroid Cancer
Triple Negative Breast Cancer
Uterine Cancer
About Us
Advertising
News
Newly Diagnosed
Treatment & Care
Survivorship
Join the Community
Newsletter
Search
Ruxolitinib
August 1, 2025
Overview of Polycythemia Vera
Charles H. Weaver, MD
August 30, 2023
Long Term Survival in Myelofibrosis Improved with Early Use of Jakafi®
Charles H. Weaver, MD
August 3, 2022
Selinexor/Jalafi Combination Shows Early Activity in Myelofibrosis
Charles H. Weaver, MD
September 19, 2021
Jakafi Does Not Increase Risk of New Cancers
Charles H. Weaver, MD
November 7, 2020
Overview of Myeloproliferative Neoplasms
Charles H. Weaver, MD
April 15, 2020
Jakafi Superior to Standard Therapy for Polycythemia Vera
Charles H. Weaver, MD
January 31, 2019
Jakafi-Interferon Combination “RUXOPEG” Promising for Treatment of Myelofibrosis
Charles H. Weaver, MD
Loading Comments...
Write a Comment...
Email (Required)
Name (Required)
Website
